Lactate Metabolism-Related Genes and Prognosis in Diffuse Large B-Cell Lymphoma
The following is a summary of “Identification of molecular clusters and a risk prognosis model for...
Read More
Search Physician’s Weekly
Search for articles, editorials, meeting coverage, podcasts, and more
Showing 1 - 20 of 236 results for 'diffuse large B-cell lymphoma'
A Challenging Diagnosis of HHV-8-Associated Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, in a Young Man with Newly-Diagnosed HIV.
BACKGROUND Human herpesvirus-8 (HHV-8)-associated diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS), is a rare form of lymphoid malignancy. It poses unique challenges in diagnosis in the setting of human...
Read MoreActivation-induced cytidine deaminase causes recurrent splicing mutations in diffuse large B-cell lymphoma.
Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma. A major mutagenic process in DLBCL is aberrant somatic hypermutation (aSHM) by activation-induced cytidine deaminase (AID), which occurs preferentially at RCH/TW...
Read MoreRole of HDL cholesterol in anthracycline-induced subclinical cardiotoxicity: a prospective observational study in patients with diffuse large B-cell lymphoma treated with R-CHOP.
Anthracycline-induced cardiotoxicity is a debilitating cardiac dysfunction for which there are no effective treatments, making early prevention of anthracycline-induced subclinical cardiotoxicity (AISC) crucial. High-density...
Read More
CAR-T Therapies Not Cost-Effective for Diffuse Large B-Cell Lymphoma
MONDAY, Dec. 4, 2023 (HealthDay News) — For patients with diffuse large B-cell lymphoma...
Read MoreEfficacy and safety of Orelabrutinib-based regimens in diffuse large B-cell lymphoma: a single-center retrospective analysis.
Currently, combining chemotherapy with Bruton tyrosine kinase inhibitors (BTKi) has demonstrated significant effectiveness in treating patients with diffuse large B-cell lymphoma. Orelabrutinib is a second-generation BTK...
Read More
Follicular Lymphoma and Diffuse Large B-cell Lymphoma with BCL2 and IRF4 Rearrangements in Adult Patients.
Follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) with concurrent BCL2 and IRF4...
Read More![[Polatuzumab vedotin, bendamustine, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma, including the outcome as a bridging treatment to CAR-T cell therapy or allogeneic hematopoietic stem cell transplant].](https://cdn.physiciansweekly.com/wp-content/uploads/2023/08/surgery-surgeons.jpg)
[Polatuzumab vedotin, bendamustine, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma, including the outcome as a bridging treatment to CAR-T cell therapy or allogeneic hematopoietic stem cell transplant].
Pola-BR (polatuzumab vedotin, bendamustine, and rituximab) therapy received approval for...
Read More
[Diagnostic and prognostic values of flow cytometry in diffuse large B-cell lymphoma with bone marrow involvement].
To analyze the diagnostic and prognostic values of flow cytometry (FC) in diffuse large B cell...
Read MoreAdvertisement
Mental health disorders and survival among older patients with diffuse large B-cell lymphoma in the USA: a population-based study.
Mental health disorders can potentially decrease quality of life and survival in patients with...
Read More
[Analysis of different protein expression levels in peripheral blood circulating tumor cells from patients with diffuse large B-cell lymphoma and their predictive efficiency for recurrence].
To analyze the expression levels of differentiation cluster 47 (CD47), signal regulatory protein α...
Read More
RCHOP Treatment Outcomes and Relapse Patterns in Primary Gastric Diffuse Large B-Cell Lymphoma
The following is a summary of “Outcome and patterns of relapse in primary gastric diffuse...
Read More
Long-term effectiveness and safety of high dose chemotherapy followed by autologous stem cell transplantation in daily practice in patients with diffuse large B-cell lymphoma.
We retrospectively evaluated long-term outcomes of high dose chemotherapy followed by autologous...
Read More
Simplified algorithm for genetic subtyping in diffuse large B-cell lymphoma.
Genetic classification helps to disclose molecular heterogeneity and therapeutic implications in...
Read More
A Rare Case of Ovarian Double-Hit/Diffuse Large B-Cell Lymphoma: A Case Report and Review of Literature.
Primary ovarian non-Hodgkin lymphoma is a rare lymphoma that is often associated with diagnostic...
Read More
ASH: Glofitamab Aids Relapsed, Refractory Diffuse Large B-Cell Lymphoma
MONDAY, Dec. 19, 2022 (HealthDay News) — The bispecific antibody that recruits T cells to...
Read More
Odronextamab Scores in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Odronextamab, an investigational bi-specific antibody targeting CD20 and CD3, showed promising...
Read More
African American Patients with Diffuse Large B-Cell Lymphoma: Predictors of Inferior Survival
African American (AA) patients with diffuse large b-cell lymphoma (DLBCL) experience differences...
Read MoreDiffuse Large B-Cell Lymphoma Patients: Impact of Circulating Lymphoma at Diagnosis on Outcomes
The most prevalent B-cell non-Hodgkin lymphoma is diffuse large B-cell lymphoma (DLBCL). Various prognostic factors were known, including the revised international prognostic index (R-IPI), MYC/BCL2 overexpression by IHC,...
Read More
HPI Novel Prognostic Predictor in Diffuse Large B-cell Lymphoma
In a recent article, researchers discussed how a unique hemoglobin-platelet index (HPI) based on...
Read More